Position statement refuting Cochrane Review in efficacy of DAA Therapy

This joint Position Statement aims to strongly refute and reject the findings of the Cochrane Review Report titled Direct-acting antivirals for chronic hepatitis C, published by the Cochrane Hepato‐Biliary Group on 6 June 2017.

The Position Statement was prepared by the expert panel who published a Consensus Statement for Australian recommendations for the management of hepatitis C for virus infection representing the Gastroenterological Society of Australia (Australian Liver Association), the Australasian Society for Infectious Diseases, the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, the Australasian Hepatology Association, Hepatitis Australia and the Royal Australian College of General Practitioners.

GESA, ASID, AHA, ASHM and Hepatitis Australia developed this position statement to urge health practitioners and patients not to be swayed by this flawed report claiming new direct-acting antivirals (DAAs) for hepatitis C do not save lives.

You can view the full position statement here.

GESA: http://www.gesa.org.au/
ASID: https://www.asid.net.au/
AHA: http://www.hepatologyassociation.com.au/
ASHM: http://www.ashm.org.au/